In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific by unknown
IN  VIVO  EFFECTOR  FUNCTION  OF  INFLUENZA  VIRUS- 
SPECIFIC  CYTOTOXIC  T  LYMPHOCYTE  CLONES  IS 
HIGHLY  SPECIFIC 
BY  ARON E. LUKACHER,  VIVIAN L. BRACIALE, AND 
THOMAS J. BRACIALE 
From the Department of Pathology, Washington University School of Medicine, St. 
Louis, Missouri 63110 
A role for cytotoxic T  lymphocytes (CTL) 1 in the host defense to viral infection 
has  been  postulated  based  on  their  capacity  to  specifically lyse  virus-infected 
syngeneic  cells  in  culture.  However,  direct  evidence  for  an  in  vivo  effector 
function  of this  T  lymphocyte subset  is  limited.  Among  the  most  definitive 
demonstrations of CTL activity in vivo are the models of host defense to primary 
virus infection in mice (1-4).  In the murine influenza system, several groups (5- 
7) have shown that adoptive transfer of immune cells possessing cytotoxic activity 
to influenza virus-infected mice promotes their recovery and reduces pulmonary 
virus titers.  The  cells with in  vivo effector activity bore  the Thy-1  and  Lyt-2 
surface markers, required K/D but not I  region homology between donor and 
recipient  for in  vivo activity, and exhibited significant influenza virus-specific 
cytotoxic activity in vitro (7).  Based on these criteria, it was deduced that CTL 
represented the T  cell subclass responsible for conferring protection in this viral 
system. However, since heterogeneous donor cell populations were used in these 
studies,  neither  the precise  identity of the  effector cell  nor  its  mechanism  of 
action in  vivo could be ascertained.  Lin and Askonas (8)  then showed that an 
influenza virus-specific cloned CTL line, which depended solely on T  cell growth 
factor (TCGF) for in vitro propagation, reduced lung virus titers and prolonged 
survival after adoptive transfer to influenza virus-infected mice. However, in a 
recent study (9),  another cloned influenza-specific CTL line examined by this 
group  failed to  alter  the  course  of influenza  infection  upon  adoptive  in  vivo 
transfer. 
Recently, there have been a series of reports (10-12)  documenting the secre- 
tion  of lymphokines,  most  notably  interferon-3,,  by  CTL  populations.  These 
findings support the hypothesis of Zinkernagel and Althage (13) that, in addition 
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to direct cytolysis, virus-specific CTL could exert their antiviral effect in vivo by 
release of lymphokines with direct or indirect antivirai activity. Since secretion 
of lymphokines by the CTL is triggered by major histocompatibility complex- 
restricted recognition of specific antigen (e.g., virus-infected cells), these lympho- 
kines might serve as a primary antiviral effector mechanism in vivo. Thus, the 
relative importance of cytolysis and soluble factors released by CTL as the CTL- 
specific antiviral effector mechanism is not yet defined. 
Our laboratory has isolated and characterized murine CTL clones directed to 
type A  influenza virus  (14).  In  this report,  we  examine the  in  vivo antiviral 
effector activity  of cloned  CTL  adoptively  transferred  into  syngeneic  mice 
lethally infected with type A influenza virus. We show that two influenza virus- 
specific CTL clones do protect recipient mice from death and mediate recovery 
from primary viral pneumonia. One CTL clone, which recognizes only type A 
influenza viruses of the H2N2  subtype in vitro, selectively promotes recovery 
from lethal influenza infection and reduces pulmonary virus titers in a subtype- 
specific fashion. In  contrast,  the other CTL clone that exhibits cross-reactive 
recognition of type A influenza virus independent of subtype in vitro, likewise 
protects mice infected by either of two different virus subtypes. When mice are 
simultaneously  infected with lethal doses of  influenza virus strains of  two different 
subtypes,  the  subtype-specific CTL clone  cannot promote  recovery.  Further- 
more, in these dual-infected animals this CTL clone can only reduce the pul- 
monary virus titer of the strain representative of the subtype recognized by this 
CTL clone. The implications of these findings to the in vivo effector mechanism 
of CTL are discussed. 
Materials and Methods 
Animals.  Male  BALB/cByJ (H-2  d) mice were purchased from The Jackson Laboratory, 
Bar Harbor, ME, and used at 7 wk of age as recipients in adoptive transfer experiments. 
Viruses.  Influenza virus strains A/JAP/57 [A/Japan/305/57 (H2N2)] and A/MEL/35 
[A/Melbourne/35 (H 1N I)] were grown in the allantoic cavity of 10-d-old embryonated 
chicken eggs and stored as infectious allantoic fluid as previously described (15). 
Cell  Lines.  The  P815  (H-2  d)  and  MDCK cell lines were  maintained in  culture in 
Dulbecco's  modified minimal  essential  medium (DMEM) (Gibco Laboratories,  Grand 
Island, NY) supplemented  with antibiotics and 10% (vol/vol) fetal bovine serum (FBS) or 
10% (vol/vol) newborn bovine serum (NBS), respectively. The MDCK  cell line was kindly 
provided by  Dr.  Virginia  S.  Hinshaw  of the  St. Jude  Children's  Research  Hospital, 
Memphis, TN. 
NeutralizingAntisera.  Rabbit anti-A/MEL/35 virus antiserum was generously provided 
by Dr. Robert Webster of the St. Jude Children's Research Hospital. Rabbit antiserum to 
purified A/JAP/57 virus hemagglutinin (HA) was prepared as described previously (16). 
Both antisera had neutralizing titers for their respective viruses of  > 1  :  100. A 1  :  10 dilution 
of each antiserum was prepared in phosphate-buffered  saline (PBS). A 1 h incubation at 
4°C  of rabbit  anti-A/MEL antiserum with  infectious  A]MEL]35  or  A/JAP/57  virus 
completely neutralized infectious A/MEL and did not affect A/JAP virus titer, as assayed 
by plaque formation on MDCK cell m0nolayers (see below). Antiserum directed to the 
A/JAP/57 HA, under the same conditions, completely neutralized  A/JAP virus without 
affecting the A/MEL virus titer. 
Cloned  CTL  Lines.  The procedures developed  to establish and maintain  influenza 
virus-specific cloned CTL lines are described in detail elsewhere (14). Briefly, spleen cells 
from BALB/c mice immunized intravenously with infectious A/JAP/57 virus 3 wk earlier 
were stimulated in vitro with A/JAP/57 virus-infected, ~,-irradiated (2,000 rad) BALB/c 816  IN  VIVO  ACTIVITY OF  ANTIVIRAL CTL  CLONES 
spleen cells.  Cloned lines were isolated by limiting dilution of viable cells from tertiary 
cultures.  The  clones  were  selected,  expanded,  and  maintained  in  the  presence  of 
A/JAP/57-infected, irradiated BALB/c spleen cells in Iscove's modified Dulbecco's me- 
dium (Gibco Laboratories) supplemented with  10% (vol/vol) FBS (Sterile Systems, Inc., 
Logan, UT), 5 x  10 -5 M 2-mercaptoethanol (2-ME), antibiotics, and 10% (vol/vol) crude 
rat T  cell growth factor (TCGF). The lines were serially passaged every 5-6 d in six-well 
cluster  tissue  culture  plates (No.  3506;  Costar,  Cambridge,  MA)  containing  20  x  106 
infected, irradiated BALB/c spleen cells and 10% TCGF. 
Intranasal Virus Inoculation of  Mice.  Mice, under light anesthesia from a diethyl ether/ 
chloroform (2:1) mixture, were inoculated by placing 50/~l of virus suspension diluted in 
cold PBS to the nose pad using a  50/~1 Eppendorf micropipette. Each mouse received a 
dose of 10 LDs0 of virus. In the dual-infection experiment described below (Results), each 
mouse was inoculated with 50 ~l of a mixture containing 10 LDs0 A/JAP/57 and 10 LDs0 
A/MEL/35 viruses. LDs0 values were calculated according to a modified Spearman and 
Karber method (17). 
Adoptive Transfer Procedure.  Viable  CTL cloned  cells,  expanded  in  six-well  cluster 
tissue culture plates as described above for routine passaging, were separated from dead 
cells according to the method of Davidson and Parish (18). The cells were washed twice 
with  Eagle's minimal essential  medium (MEM) supplemented  with  10%  (vol/vol) FBS, 
washed once with MEM, and resuspended in MEM at a concentration of 2 x  107 cells/ 
ml. A 0,5 ml vol of this resuspension (i.e., 107 cells) was injected intravenously via the tail 
vein into each mouse. Virus-infected control mice each received 0.5 ml MEM i.v. Adoptive 
transfers of CTL cloned cells were carried out within  1 h after intranasal inoculation of 
virus. 
Lung Virus Titration by MDCK Cell Plaque Assay.  Lungs were asceptically removed at 
the bronchi, snap-frozen in liquid nitrogen, and stored at -70 °C until ready for titration. 
The lungs were thawed at 4°C in  2  ml PBS supplemented with antibiotics and 0.75% 
bovine serum albumin (BSA) (670-5260; Gibco Laboratories). Lungs were then manually 
homogenized (Dounce tissue grinder) and centrifuged (3,000 g for 15 rain, 4°C).  10-fold 
dilutions of lung extract supernatants were prepared in PBS supplemented with 0.75% 
BSA, 0.1  g/1 MgCls, 0.1  g/I CaCI~, and antibiotics. MDCK cell monolayers were prepared 
by seeding  2  x  10 s  MDCK  cells  in  2  ml  DMEM  supplemented  with  10%  NBS  into 
individual  wells  of 12-well  cluster tissue culture  plates (No.  3512;  Costar);  monolayers 
attained confluency after 2 d at 37°C in a 7% COs humidified atmosphere. 100 #1 of the 
appropriate dilution was added to each monolayer and incubated at room temperature 
for 30  min. Each well then received  1.5  ml of agar overlay medium containing MEM, 
1.5%  BSA,  2% amino acids (320-1130;  Gibco Laboratories),  1%  vitamins (320-1120; 
Gibco Laboratories), 2 mM glutamine (320-5030;  Gibco Laboratories), antibiotics,  1% 
agar (Difco Laboratories, Inc., Detroit, MI), and 0.5 vg/ml trypsin-TPCK (Worthington 
Biochemical Corp., Freehold, NJ). After 2 d incubation in 7% COs at 37°C, 0.5 ml of a 
second agar overlay containing 0.01% neutral red, but no trypsin, was added to each well. 
The plates were incubated for 18 h and plaques were then counted. Each titration point 
of an individual lung extract was assayed in duplicate. Results are expressed as the mean 
plaque-forming units (PFU)/ml _  SEM in lung extracts from three mice. 
In the case of dual infection (simultaneous infection of mice with the A/JAP/57 and 
A/MEL/35 viruses), in order to quantitate the level of each virus in the lungs, the lung 
extracts were treated with anti-A/MEL/35 antiserum or anti-A/JAP/57 HA antiserum as 
described above before plaquing. Controls consisted of untreated extracts. 
Assay  for Cell-mediated Cytotoxicity.  The 5aCr-release cytotoxicity ~assay was carried out 
as described  (15).  Briefly,  1 X  104  ~Cr-labeled uninfected  or influenza virus-infected 
P815 target cells were added to individual wells of 96-well, flat-bottom microtiter tissue 
culture plates in a 0.1  ml vol of MEM +  10% FBS.  Effector cells were cloned CTL and 
were added in a 0.1  ml vol of MEM +  10% FBS to each well. The plates were incubated 
at 37°C  in  7%  COs for 6  h.  From each well,  0.1  ml of supernatant was removed and 
counted  in  a  Beckman  4000  Gamma Counter  (Beckman  Instruments,  Inc.,  Fuilerton, 
CA). The percent specific 5tCr release was calculated from the formula: [(test counts - LUKACHER,  BRACIALE, AND  BRACIALE  817 
spontaneous retease)/(total counts -  spontaneous release)]  x  100.  Spontaneous release 
from target cells incubated with medium alone usually ranged from 8 to  15% of total 
counts. Total release was determined by target cell solubilization in  1% Triton X-100 
(Sigma Chemical Co., St. Louis, MO). Release values represent the mean percent specific 
5tCr release from four replicate wells. SEM were always <5% of the mean value and are 
omitted. 
Assays of Cellular Proliferation.  Two methods were used to assess the proliferative 
response of the cloned CTL lines:  direct estimates of cell  concentration in stationary 
phase (day 5 of culture) and [SH]thymidine ([SH]TdR)  incorporation at the peak of the 
proliferative response (day 3 of culture). Cell lines were subcultured as described above. 
6-7 d after antigenic stimulation, cloned cells were resuspended in fresh medium contain- 
ing  10%  (vol/vol) TCGF.  After 7  d  in culture,  1 x  104  viable  cells  were plated into 
individual wells of 96-well  flat-bottom tissue culture plates (Linbro, Flow Laboratories, 
Inc., Hamden, CT), along with 106 irradiated, uninfected or virus-infected BALB/c spleen 
cells in 0.2 ml of RPMI 1640 medium supplemented with 10% (voi/vol) FBS, 5 X 10  -5 M 
2-ME, antibiotics, 10 mM Hepes, and 10% (vol/vol) TCGF. At 3, 4, and 5 d of culture at 
37 o  C, the proliferative response of quadruplicate cultures was assessed by adding to each 
well 0.1 ml of PBS containing 1 uCi [SH]TdR. After 4-h incubation at 37°C, individual 
wells were harvested onto glass fiber filters by using an automated harvester. Radioactivity 
was detected by standard scintillation methods. Results are expressed as the mean cpm + 
SEM of quadruplicate cultures. Viable cell concentrations in companion microwells were 
determined by trypan blue exclusion. 
Cell Surface Phenotyping.  The expression of Thy-1, Lyt-1, and Lyt-2 on the surface of 
these clones was detected using monoclonal reagents as described in detail elsewhere (14). 
Results 
Influenza Virus Specificity of CTL Clones In Vitro.  The two cloned CTL popu- 
lations used in this study, A4 and A7, were selected by limiting dilutions from 
an in vitro tertiary culture of spleen cells derived from an A/JAP/57 influenza 
virus-immunized  BALB/c  mouse.  The  clones  were  isolated,  expanded,  and 
maintained  in  the  presence  of  A/JAP/57  virus-infected  irradiated  BALB/c 
spleen cells and 10% crude interleukin 2 (IL-2)-conditioned medium of rat spleen 
cell  origin.  Cell  surface  phenotyping  (14)  of these  clones  revealed  that  both 
clones are Thy-l.2  +, Lyt-l-2  + (data not shown). These two clones of H-2 d origin 
were restricted by H-2  d gene products in the recognition of A/JAP/57 virus both 
at the level of target cell lysis and antigen-dependent proliferation. Patterns of 
H-2-end  restriction  of the clones were  determined by the ability of the  CTL 
clones to lyse a  panel of A/JAP/57 virus-infected L929 (H-2 k) cells transfected 
with either the H-2K  d, H-2L  d, or H-2D  d gene (unpublished observations). In this 
manner,  A4  and  A7  were  determined  to  be  restricted  by  H-2K  d and  H-2L  d, 
respectively. At  the time of this  study, both  cloned  lines had been  carried  in 
continuous culture for over one year without any changes in morphology, growth 
characteristics, surface phenotype, or viral antigen specificity. 
The viral antigen specificities of the A4 and A7 clones at the level of target 
cell  recognition  is  shown in  Table  I.  A4  recognizes an  antigenic determinant 
shared by type A influenza viruses of the H2N2 subtype, e.g., A/JAP/57 and A/ 
AA/67, and exhibits no cytotoxic activity against cells infected with either A/ 
MEL/35  (H1N1  subtype)  or  A/HK/68  (H3N2  subtype).  This  is  the  typical 
pattern of subtype-specific CTL recognition reported previously (I 4). In contrast, 
A7 is directed to a viral antigen determinant common to type A  influenza virus 
strains of different subtypes, e.g., A/JAP/57 (H2N2),  A/MEL/35 (H1N1), and 818  IN  VIVO  ACTIVITY  OF  ANTIVIRAL  CTL  CLONES 
TABLE  I 
Influenza Virus Specificity of CTL Clones 
CTL  line 
Effector/  Percent specific ~tCr release from target cells* 
target  Unin-  A/JAP/57  A/AA/67  A/MEL/35  A/HK/68 




0.5:1  0  48  35  0  1  0 
1:1  0  66  52  2  2  1 
2:1  0  84  67  2  2  1 
0.5:1  0  52  58  57  43  0 
1:1  0  76  76  77  54  0 
2:1  0  85  88  89  62  1 
CTL  lines were examined for cytotoxic activity on uninfected and infected 5tCr-labeled target cells 
5  d  after routine subculturing in the presence of 10% TCGF-supplemented  medium  and A/JAP/ 
57 virus-infected irradiated BALB/c  splenocytes. 
*  Values are the means from four replicate wells with spontaneous release subtracted. Spontaneous 
release from all target groups was <13%.  SEM are <5%  of mean values and are omitted. 
* 1 x  104 P815 (H-2  °) target cells were added per well. 
TABLE  II 
Viral Antigen and Growth Factor Dependence of CTL Clone Proliferation 
BALB/c stimulator 
spleen cells in- 
fected with:* 
Final cell concentration 
(x lOS/mO  t  Peak proliferative response! 
A4  !  A7  A4  A7 
+  --  +  --  +  --  +  - 
--  0.7  0.1  2.5  <0.1  221-+11  604-10  1,2004-119  414-2 
A]JAP/57  7.4  0.3  16.8  0.1  6,286 4- 75  59 4- 3  34,961 4- 1,626  362 4- 21 
A/AA/67  8.1  0.1  18.3  2.0  15,225 4- 220  95 4- 13  53,344 4- 1,334  2,831 4- 331 
A/MEL/35  1.0  <0.1  17.5  0.6  1,106 4- 151  52 4- 4  22,697 4- 1,215  1,534 4- 240 
A/HK/68  1.0  0.1  16.8  0.3  363 4- 49  56 4- 4  25,213 4- 1,176  391 4- 43 
B/Lee  1.3  0.5  4.8  0.1  7844-35  41 4-2  4,8024-310  444-8 
CTL lines A4 and A7 were subcultured in medium containing 10% crude TCGF and irradiated BALB/c spleen cells infected with 
A/JAP/57  virus. After 6 d of culture,  cells of each line were resuspended in fresh medium containing  10% crude  TCGF and 
cultured for an additional 7 d. After this time, replicate cultures of 104 viable cells were analyzed for proliferation by [SH]TdR 
incorporation and direct cell counting after culturing under the indicated conditions. 
* Normal BALB/c spleen cells after 2,000 rad of irradiation were either infected with the indicated virus strain or left uninfected. 1 
x  10  s cells were co-cultured with 1 x  10  4 cloned CTL cells as described (Materials and Methods). 
* Values are the viable cell concentrations at day 5 of culture. The starting cell concentration (day 0) was 0.5 x  10S/ml. 
! Values are the mean cpm ± SEM of [SH]TdR incorporation from quadruplicate cultures at the peak of the proliferative response 
(day 3). 
I Cells of the indicated clone were cultured with the indicated splenocyte stimulator either in the presence (+) or absence (-) of 10% 
crude TCGF. 
A/HK/68  (H3N2), and has the characteristic pattern of viral antigen recognition 
of cross-reactive  CTL clones (14). As reported previously (19), the specificity of 
IL-2-dependent,  antigen-specific  proliferation  of these  clones  in  vitro  directly 
parallels  their  cytolytic  effector  specificity  (Table  II).  Thus,  A4  proliferates 
significantly only  in response  to  stimulation  by A/JAP/57  virus-  or  A/AA/67 
virus-infected,  irradiated BALB/c  spleen cells. A7, on the other hand, prolifer- 
ates  in the presence  of irradiated  BALB/c  spleen  cells infected  with viruses  of 
either  of the  three  subtypes  represented  here.  Importantly,  both  clones  were 
dependent  on both antigen  and exogenous  IL-2  for proliferation;  i.e.,  neither LUKACHER,  BRACIALE,  AND  BRACIALE  819 
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FIGURE  1.  Viral antigenic specificity of in vivo antiviral effector activity of CTL clones A4 
and A7. BALB/c mice were inoculated intranasaliy with 10 LDs0 of either A/JAP/57 virus (A) 
or A/MEL/35 virus (B). Within 1 h of infection, groups of four mice each received either 1 x 
107  cells of clone A7  (---),  1  x  107  cells of clone  A4  (--.--),  or  were  left  untreated 
(--). Cumulative mortality was tabulated for 20 d. 
A4  nor  A7  proliferates  to  a  specific antigenic stimulation  in  the absence  of 
exogenous IL-2. 
In Vivo Effector  Function of Cloned  CTL Lines.  To assess  the in vivo effector 
function of CTL clones, the following protocol was used. Panels of syngeneic or 
allogeneic mice were inoculated with 10 LDs0 of infectious virus by the intranasal 
route. 1 h after lethal infection, 107 cloned cells were adoptively transferred into 
test recipients intravenously via the tail vein. Control infected recipients received 
medium with  no  cells.  These  test and control recipients were monitored for 
overall survival and pulmonary virus titer as described below. This overwhelming 
lethal inoculating virus dose was used to minimize the effect of the endogeneous 
host response on the outcome of infection. As described below (Fig.  1), both the 
A/JAP/57  and  A/MEL/35  virus  infections were uniformly lethal  by  7-10  d 
postinoculation. 
Since previous reports had demonstrated that after adoptive transfer, hetero- 
geneous immune cell populations  possessing cytotoxic activity protected mice 
from lethal primary influenza virus pneumonia, our initial experiments sought 
to verify that cloned CTL could mediate this antiviral effect in vivo. As shown 
in Fig.  1 A, both the subtype-specific A4 clone and the cross-reactive A7 clone 
completely protected mice from death by A/JAP/57 (H2N2) influenza virus, the 
virus subtype used to select and maintain the clones in vitro. In contrast, while 
the cross-reactive A7 clone promoted recovery of recipients from lethal infection 
with A/MEL/35  (H1N1) virus, the subtype-specific clone A4 had no effect on 
the lethal  outcome of A/MEL/35  infection after adoptive transfer (Fig.  1B). 
Neither clone altered the outcome of lethal infection with the unrelated B/Lee 
virus and the in vivo protective effect of the clones is H-2 restricted (Lukacher, 
BraciaM,  and  Braciale,  manuscript  in  preparation).  Thus,  the  viral  antigenic 
specificity exhibited by these CTL clones in vitro in cytotoxicity (Table I) and 
proliferation assays (Table II) precisely parallels the specificity of their in vivo 
capacity to confer protection from lethal primary influenza pneumonia (Fig.  1). 
The association of recovery from primary influenza pneumonia with falling 820  IN  VIVO  ACTIVITY  OF  ANTIVIRAL  CTL  CLONES 
TABLE  III 
Specificity of  Pulmonary Virus Reduction by CTL Clone A4 
Cloned CTL  Recipients 
cells trans-  Virus instilled intra- 
ferred*  nasally*  Virus titer in lungs  i 
None  A/JAP/57 (H2N2)  (1.61  __. 0.30) x  106 
A4  A/JAP/57  <100 
None  A/MEL/35 (H1N1)  (2.07 __. 0.52) x  106 
A4  A/MEL/35  (2.00 +  0.45) x  106 
*  1 X  10  7 cells of cloned CTL line A4 were injected intravenously into 
each  BALB/c  recipient at  the  same  time as  virus  infection.  Control 
infected mice received 0.5 ml medium i.v. 
* Recipient mice were inoculated intranasally with  10 LDs0  of the indi- 
cated influenza type A virus strain. Virus subtype appears in parentheses. 
g Expressed as mean PFU/ml +  SEM of lung extracts from three individ- 
ual  mice at  day  5  after infection as assayed by plaque  formation on 
MDCK cell monolayers (Materials and Methods). 
pulmonary virus titers has been well documented (3, 5, 20). In light of the failure 
of clone A4 to protect across subtypes, it was of interest to correlate protection 
by A4 with reduction in pulmonary virus titers in A/JAP/57- and A/MEL/35- 
infected recipients. Infectious virus particles in mouse lung extracts were titered 
by plaque formation on monolayers of MDCK cells.  In preliminary studies, a 
kinetic analysis of lung virus levels in mice infected with 10 LDs0 of A/JAP/57 
virus which received  107  cloned CTL cells i.v.  demonstrated that  pulmonary 
virus titers progressively decreased from 24 to 96 h after infection, with a  100- 
1,000-fold reduction in infectious particles attained by 96 h after infection. No 
virus was detectable in lungs of recovered mice at 3 wk postinfection, the end of 
the  observation  period  for  the  protection  studies  described above  (data  not 
shown). Based on these considerations, for the present studies pulmonary virus 
titers were measured 5  d  postinfection. Table  III  shows the pulmonary virus 
titer at 5 d postinfection with A/JAP/57 or A/MEL/35 of control recipients and 
recipients of 107 adoptively transferred A4 cells administered at day 0. Transfer 
of clone A4 is associated with a  >l,000-fold reduction in virus titer from the 
lungs  of  A/JAP/57-infected  recipients,  but  clone  A4  has  no  effect  on  the 
pulmonary  viral  titer  in  A/MEL/35-infected  recipients.  As  described  below 
(Table IV), clone A7 efficiently reduces the pulmonary virus titer of both A/ 
JAP/57- and A/MEL/35-infected recipients. Hence, pulmonary virus titer cor- 
relates with the recovery of cloned cell recipients, and both survival data and 
pulmonary viral titers demonstrate the subtype-specific behavior of clone A4 in 
vivo. 
In Vivo Effects of Cloned  CTL Lines in Mice Simultaneously  Infected  with A/JAP/ 
57 and A/MEL/35 Viruses.  The subtype-specific effector activity of clone A4 in 
vivo afforded the opportunity to examine the specificity of the antiviral effector 
mechanism used to eliminate virus and promote recovery in vivo. Since specific 
antigenic recognition appears to be necessary to trigger lymphokine release by 
CTL (11,  12), it is possible that soluble mediators released by specific induction 
with antigen  could act nonspecifically to  promote recovery. To examine this 
issue, panels of mice were simultaneously infected with 10 LD~0 of both A/JAP/ LUKACHER,  BRACIALE,  AND  BRACIALE  821 
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FIGURE  2.  Ability of cloned CTL  lines A4 and A7  to promote recovery of mice infected 
simultaneously with virus strains of two different type A  influenza virus subtypes. Protocol is 
as described in Fig. 1, except that recipients were inoculated simultaneously with 10 LDs0 A/ 
JAP/57 virus and  10 LDs0 A/MEL/35 virus. 
57 (H2N2) and A/MEL/35 (H1N1) virus and then inoculated with either clone 
A4 (H2N2 subtype specific) or A7 (type A cross-reactive) according to the above 
protocol.  The  survival  curves for  these  various  groups  are shown  in  Fig.  2. 
Control  mice  that  were  dually  infected but  received no  cells  had  a  slightly 
accelerated  mortality  (time  to  death,  4-6  d)  compared  with  either  lethally 
infected A/JAP/57  recipients (time to death, 6-8  d) or A/MEL/35  recipients 
(time to death, 8-10 d). Recipients of the cross-reactive A7 clone, on the other 
hand,  were completely protected from the lethal dual infection.  Most impor- 
tantly, subtype-specific clone A4 failed to promote recovery of these dual-infected 
recipients whose mortality curve was similar to the curve of A/MEL/35 infection 
(Fig.  1 B). 
The exquisite specificity of the antiviral effector activity exhibited by A4 in 
vivo was further substantiated by measurements of pulmonary virus titers at day 
5 after simultaneous A/JAP/57  and A/MEL/35  infection. As shown in Table 
IV, clone A4 dramatically decreased the level of infectious A/JAP/57 virus by 
>l,000-fold relative to controls but failed to reduce the titer of infectious A/ 
MEL/35  in  these  dual-infected  lungs.  Thus,  the  clone  is  able  to  efficiently 
eliminate one virus in the face of high levels of another related but antigenically 
distinct virus.  On the other hand, A7  not only reduces A/JAP/57  pulmonary 
titers to the same extent as A4,  but also decreases A/MEL/35  virus levels ~2 
logx0 units below that of control mice. Had pulmonary virus titrations for the 
group that received A7 been determined at time points beyond 5 d postinfection, 
complete elimination of A/MEL/35  would have been achieved. The fact that 
this group recovered from this dual infection supports this claim. Furthermore, 
the gross appearance of lungs of these mice at 3 wk postinfection was indistin- 
guishable from those of normal mice, further suggesting that infectious virus 
had been eliminated before the development of irreversible pulmonary damage. 
Discussion 
In  this  report  we  have  demonstrated that  cloned populations  of influenza 
virus-specific  CTL  maintained  in  continuous  long-term  culture  (>1  yr)  can 822  IN  VIVO  ACTIVITY OF  ANTIV1RAL  CTL CLONES 
TABLE IV 
Pulmonary Virus Titer Reduction  Mediated by CTL Clones in Mice Simultaneously  Infected 
With Influenza Type a  Virus Strains of Different Subtypes 
Pulmonary Virus Titer of Dually Infected Recipients* 
Cloned 
CTL cells  Viral specificity  of  Total Virus 
transferred  cloned CTL line  (A/JAP + A/  A/JAP  j  A/MEL  I 
MEL)* 
None  --  (2.0 + 0.6) x  106  (4.8  + 1.4) x  105  (1.2  + 0.5) x  106 
A4  Subtype specific  (1.8 -4- 0.5) X 10  6  <100  (2.0 + 0. I) X 106 
A7  Cross-reactive  (2.0 + 1.0) x  104  <100  (2.5 + 1.4) x  104 
Recipient mice were simultaneously inoculated with 10 LDs0 A/JAP/57  virus and  10 LDs0 A/ 
MEL/35 virus intranasally. Immediately after infection, 1 ×  10  7 cells of either clone A4 or clone 
A7 were injected intravenously into panels of infected recipients. Controls consisted of dually 
infected mice that had received no cells. 
* Lung extracts prepared from recipients 5 d after infection were treated for 1 h at 4°C with rabbit 
anti-A/MEL/35  antiserum, goat anti-A/JAP/57  HA antiserum, or no antiserum,  before  virus 
titration of MDCK cell monolayers. 
Indicates total infectious virus titer expressed as mean PFU/ml +  SEM of lung extracts from three 
dually infected mice per value. 
0 Residual infectious virus titer after treatment with neutralizing anti-A/MEL/35 antiserum. 
I Residual infectious virus titer after treatment with neutralizing anti-A/JAP/57  HA antiserum. 
mediate recovery from lethal influenza virus infection. The viral specificity of in 
vivo protection by the clones directly corresponds to their in vitro specificity as 
defined in cytotoxicity and proliferation assays.  Thus, specific antigenic recog- 
nition  appears  to  be  required  for  the  expression  of in  vivo ant!viral  activity. 
Furthermore,  the  protective effect of the  cloned  CTL  is  associated  with  the 
specific elimination of infectious virus from the lungs of recovering animals. This 
result suggests a direct effect of the CTL on the viral infection process. 
A major finding in this study is the observation that the H2N2 subtype-specific 
clone A4 is unable to alter the lethal outcome of simultaneous infection with the 
A/JAP/57  (H2N2)  and  A/MEL/35  (H1N1)  viruses.  In  these  dually  infected 
recipients, A4 reduced the pulmonary titers of A/JAP/57  virus by at least three 
orders of magnitude but the clone failed to decrease the titer of the A/MEL/35 
virus.  The clone therefore was able to selectively inhibit the replication of the 
specifically recognized influenza strain without affecting the titer of the irrelevant 
influenza virus strain. Also, the mortality curve for this dual infection group was 
similar  to  that  of A/MEL/35-infected  recipients  of clone  A4.  This  strongly 
suggests that the A4 recipient mice had eliminated the A/JAP/57 virus and died 
of A/MEL/35 pneumonia.  In contrast, the cross-reactive A7 clone reduced the 
pulmonary titers  of both  viruses  in  the  dual-infected  recipients and  promoted 
complete recovery. 
These  results  have  two  related  implications.  First,  they  imply  that  in  this 
experimental system the CTL clones are probably not expressing their ant!viral 
effect in vivo primarily by orchestrating nonspecific host defense mechanisms in 
the  recipients.  More  importantly,  these  results  favor  the  concept  that  CTL 
mediate  their  ant!viral  protective  effect  in  vivo  via  direct  cytolysis  of virus- 
infected cells. Although we cannot at present rule out the involvement of short- 
lived soluble  mediators  released  by the  clones  in  high  local  concentrations,  it LUKACHER, BRACIALE, AND  BRACIALE  823 
seems highly unlikely that  the antiviral  effect of the clones in  vivo is  due to 
antigen-nonspecific lymphokines, e.g., interferon-y, produced by the CTL after 
specific antigenic stimulation.  In this connection, it should be noted that both 
clones can secrete interferon after stimulation with mitogenic lectins or virus- 
infected target cells (unpublished observations). 
It is of considerable interest that these protective CTL clones require both 
specific antigenic stimulation and an exogenous source of IL-2 for their in vitro 
propagation.  This observation is at variance with the findings of Engers et al. 
(21).  These  investigators showed that  alloreactive CTL  clones dependent on 
antigen and exogenous growth factors for in vitro growth failed to express in 
vivo effector activity, whereas autonomously proliferative CTL clones (22,  23) 
were effective in  vivo.  In  our  hands,  both  autonomous and exogenous IL-2- 
dependent anti-influenza CTL clones showed similar levels of antiviral activity 
in vivo (unpublished observations). Furthermore, in preliminary studies, adoptive 
transfer of limited numbers of these  IL-2-dependent CTL  clones after lethal 
irradiation  to  inhibit proliferation did result in  prolonged survival of lethally 
infected recipients, but complete recovery of all recipients did not occur. It is 
therefore possible that these antigen- and exogenous growth factor-dependent 
clones need not proliferate in vivo to express an antivirai effect. 
Another consideration thought to explain the success or failure of cloned CTL 
to  exhibit  effector activity in  vivo is  altered cell  trafficking of these  in  vitro 
propagated clones, most notably nonspecific trapping of cells in the pulmonary 
vasculature (24).  At present we do not believe that  the expression of in  vivo 
effector activity by the clones reported here is due to nonspecific trapping of the 
clones at the site of antigenic sequestration, the infected lung.  Cell trafficking 
studies using autoradiographic detection of biosynthetically labeled clone cells 
indicate  that  the  cells  leave  the  pulmonary  vasculature  and  migrate  to  the 
pulmonary parenchyma and alveolar spaces of both infected and uninfected mice 
(unpublished observations). 
A  number of host defense mechanisms, both specific and nonspecific, have 
been implicated as antiviral effectors in protection and recovery from infection 
(25).  In experimental models of viral infection, the importance of a  particular 
defense mechanism in recovery appears to depend on both the type of virus and 
the  severity  of  infection.  For  example,  natural  killer  cell  activity  has  been 
demonstrated to have a significant antiviral effect on infection with some viruses 
but not others (26, 27). The data presented here strongly suggest that antiviral 
CTL represent an extremely potent effector mechanism at least for influenza 
infection. Even under the conditions of overwhelming infection used for these 
studies, as few as  1-2  x  106 cloned CTL could prolong survival and promote 
recovery of a  significant percentage of lethally infected recipients (A.  E.  Lu- 
kacher, unpublished observations). It is anticipated that, with infection at minimal 
lethal virus doses, perhaps as few as 105 cells or less of a particular clone could 
be protective in vivo. Studies detailing the antiviral effect of adoptively trans- 
ferred CTL clones will be needed in a number of different viral systems to better 
define the role of this T  cell subset in recovery from infection. 
In  conclusion, we have demonstrated that  cloned populations  of influenza- 
specific CTL propagated in the presence of specific antigen and an exogenous 824  IN  VIVO ACTIVITY OF ANTIVIRAL CTL  CLONES 
IL-2 source can efficiently eliminate  infectious virus from the lungs of lethally 
infected  mice  and  promote  recovery.  Both  the  induction  and  expression  of 
antiviral activity by the CTL clones in vivo is highly specific from the standpoint 
of viral  antigen  recognition.  It  therefore  seems  likely  that  direct  cytolysis of 
virally  infected  cells  is  the  primary  mechanism  by which  CTL  express  their 
antiviral  effector activity in  vivo.  The  availability of cloned  CTL  with  in  vivo 
functional activity should now enable study of the molecular basis of the in vivo 
effects of CTL. 
Summary 
Cloned  lines  of murine  cytotoxic T  lymphocytes (CTL) directed  to  type A 
influenza virus confer complete protection upon adoptive transfer to syngeneic 
mice lethally infected by influenza virus. The exquisite specificity exhibited by a 
subtype-specific cloned CTL  in  culture  is reflected in  its capacity to eliminate 
pulmonary virus and mediate recovery only in those mice infected by the virus 
subtype recognized by this cloned line in vitro. A cross-reactive CTL cloned line 
protects mice infected by either of two influenza virus subtypes. In mice dually 
infected with  two virus subtypes, the subtype-specific CTL clone only reduces 
lung virus levels of the recognized virus subtype and cannot prevent these mice 
from dying.  In contrast,  adoptive transfer of the cross-reactive CTL clone into 
mice  simultaneously  infected  with  two  virus  subtypes results  in  reduction  of 
pulmonary titers of both subtypes and promotes complete recovery. These results 
directly implicate CTL as an important  antiviral  defense mechanism  in experi- 
mental  influenza  infection.  In  addition,  these  results  indicate  that  both  the 
induction  and expression of antiviral  effector activity by CTL in vivo is highly 
specific and therefore favor the concept that CTL express their antiviral  effect 
in vivo by direct cytolysis of infected cells. 
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